Replies to post #243618 on Biotech Values

[DewDiligence]

BMY -5% on Milvexian phase-2 data reported yesterday.

[DewDiligence]

Milvexian addendum—in #msg-169809402 I said:

…BMY/JNJ have committed to a phase-3 program for Milvexian in three indications: secondary stroke prevention [SSP]; ACS; and primary stroke prevention in patients with AF… Curiously, the three phase-3 indications do not include either of the indications tested in phase-2, which are treatment of acute ischemic stroke…and VTE prevention…

On rereading the above I find that it’s somewhat misleading. I.e., from a practical standpoint the phase-3 trial in SSP is in almost the same indication as the just-completed phase-2 trial. The phase-2 enrolled only patients experiencing an acute stroke, but the endpoint of consequence was the prevention of a recurrent stroke, which is the definition of SSP.